Form 8-K - Current report:
SEC Accession No. 0001178913-25-002784
Filing Date
2025-08-12
Accepted
2025-08-12 08:31:35
Documents
15
Period of Report
2025-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2533609.htm   iXBRL 8-K 49081
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 137284
7 image00004.jpg GRAPHIC 3406
  Complete submission text file 0001178913-25-002784.txt   377863

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250812.xsd EX-101.SCH 4627
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250812_def.xml EX-101.DEF 18273
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250812_lab.xml EX-101.LAB 27771
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250812_pre.xml EX-101.PRE 20515
18 EXTRACTED XBRL INSTANCE DOCUMENT zk2533609_htm.xml XML 6564
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)